Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 43 results found. Search for [ Glivec ]

Results 1 to 21 of 43
Rajeev Dubey
New Delhi, September 3, 2018
Prathiba singh has contributed to some of the most important IPR laws and given landmark judgments.

E. Kumar Sharma
New Delhi, January 10, 2018
By following the strategy of doing a few things well, V.C. Nannapaneni has helped Natco Pharma carve out a space for itself.

E Kumar Sharma
June 3, 2016
\"Real, meaningful progress remains elusive, and recent signals indicate backsliding in key areas. For instance, India just released its long-awaited National Intellectual Property Rights Policy, which falls far short of industry expectations.\"

E Kumar Sharma
May 11, 2016
A good 14 years after it sought patent in India for its blockbuster Hepatitis C drug, marketed as Sovaldi, the approval, by the Deputy Controller of Patents & Designs, must have come as a big relief to Gilead Sciences.

E. Kumar Sharma
April 28, 2015
One leading industry representative saw in the PM's statement \"a clear signal to bureaucracy not to resist TRIPs Plus measures such as Patent Linkage, Data Exclusivity, Dilution of Section 3(d) and Declaration of No-use of compulsory license.\"

P.B. Jayakumar
March 15, 2015
\"My biggest challenge is continuing the accelerated growth agenda of the company with key focus on the patients we serve,\" Meenakshi Priyam, Head-HR, Novartis India, says.

PB Jayakumar
January 15, 2015
The patent was rejected on the basis that \"minor changes in the molecule\" did not improve efficacy of the drug.

E Kumar Sharma
January 17, 2015
The Indo-US talks in January, to be held just days before President Barack Obama visits India to attend the Republic Day celebrations, are part of a work plan on IPR agreed upon by both nations in November.

E Kumar Sharma
December 18, 2014
Experts say the Novartis-Cipla case raises similar issues that previous cases did - non-availability of drugs, non-working of patent in India and unaffordable pricing.

Mail Today Bureau
New Delhi, May 2, 2014
Commerce secretary Rajeev Kher bluntly said that the government will not take part in any unilateral probe by the US on its IPRs. He said that all issues between the two countries, including those related to IPR, should be discussed at the US India Trade Policy Forum.

Sumeet Chatterjee and Ben Hirschler
Mumbai/London, February 6, 2014
Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent.

New Delhi, August 28, 2013
In reply to allegations made by Novartis on India's 'discriminatory' patent practices, the government has said global firms have benefited more from the country's rules than suffer from them.

Mumbai, August 2, 2013
The Intellectual Property Appellate Board (IPAB) has revoked the patent granted to the British drug major GlaxoSmithKline Pharma for its breast cancer drug Tykerb.

E. Kumar Sharma
May 9, 2013
Y.K. Hamied steps down as managing director of Cipla in February. His decision to function as non-executive chairman from April 1 and other management changes are significant. The move is part of a major transformation aimed at propelling the company into a new orbit.

Associated Press
New York, April 25, 2013
The US government has sued Novartis Pharmaceuticals Corp, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.

E. Kumar Sharma
May 6, 2013
India is the world's third-largest pharmaceuticals market in terms of volumes, but competition is stiff to grab a slice of the rapidly growing business. Several small pharma companies are making a big difference in niche areas of health-care.

New Delhi, April 11, 2013
Painting a favourable picture for the domestic pharmaceutical companies, ICRA said balance sheets of major pharmaceutical companies remain strong and provide adequate room for fund raising if required.

New Delhi, April 10, 2013
The US pharmaceuticals major is fighting a single judge bench order refusing to restrain Glenmark Pharmaceuticals from manufacturing and selling anti-diabetes drugs Zita and Zita-Met.

E. Kumar Sharma
April 13, 2013
The Supreme Court decision on Glivec sets the tone for other patent disputes and puts global drugmakers on the back foot.

Himanshu Kane
April 25, 2013
The apex court's judgment in the Novartis case strikes the right balance between public and inventor interest.

PAGES 1 OF 3  123